In spite of significant advancements in cancer treatment, patients with cancer still have a poor prognosis and poor therapeutic outcomes. Combining chemotherapy and immunotherapy drugs, called chemo-immunotherapy, offers promise by harnessing the synergistic effects of these two treatments. In addition to reducing drug dosages, this strategy optimizes therapeutic efficacy, making it a viable option for treating cancer.A nano-based drug delivery system (NDDS) was developed as a result of nanotechnology integration into cancer therapy. Chemotherapeutic agents are encapsulated within nanocarriers, offering advantages such as site-specific release of drugs and responsiveness to the tumor microenvironment.Many nanocarriers have been approved to treat cancer, including liposomes, nanoparticles, and micelles. Comparatively to traditional formulations, they have demonstrated significant improvements in therapeutic efficacy.Cancer treatment could be revolutionized with the application of NDDS to chemoimmunotherapy. Cancer patients can benefit from this approach by improving therapeutic outcomes, minimizing adverse side effects, and optimizing clinical outcomes. Recent advancements in NDDS tailored for chemoimmunotherapy are discussed in this discussion of the current landscape of cancer immunotherapy and chemoimmunotherapy